Skip to main content

Table 1 Patient characteristics at baseline a

From: Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

  Abatacept (n = 43) Rituximab (n = 46) TNFi (n = 50) Total (n = 139) P -value
Mean age (SD), yr 56.16 (9.95) 57.09 (11.08) 55.81 (12.53) 56.34 (11.24) 0.852
Female sex, % 88.4 (n = 38) 63.0 (n = 29) 74.0 (n = 37) 74.8 (n = 104) 0.022
Median disease duration (IQR), yr 6.56 (2.56 to 11.96) 7.60 (3.22 to 16.25) 5.64 (1.79 to 12.00) 6.25 (2.43 to 14.30) 0.174
RF-positive, % 56.4 (n = 22) 80.0 (n = 36) 62.5 (n = 30) 66.7 (n = 88) 0.054
Mean DAS28 (SD) 4.74 (1.46) 4.87 (1.24) 4.92 (1.11) 4.84 (1.26) 0.805
Mean HAQ-DI (SD) 1.46 (0.64) 1.39 (0.71) 1.37 (0.65) 1.40 (0.66) 0.822
Median previous csDMARDs (IQR), n 2 (2 to 3) 3 (2 to 3) 2 (2 to 3) 2 (2 to 3) 0.192
Comedication, %      0.894
  csDMARD + Corticosteroidb 20.9 (n = 9) 28.3 (n = 11) 28.0 (n = 14) 25.9 (n = 36)  
  csDMARDb 41.9 (n = 18) 50.0 (n = 23) 38.0 (n = 19) 43.2 (n = 60)  
  Corticosteroid 11.6 (n = 5) 8.7 (n = 4) 10.0 (n = 5) 8.6 (n = 12)  
  None (biologic monotherapy) 25.6 (n = 11) 17.4 (n = 8) 24.0 (n = 12) 22.3 (n = 31)  
  1. acsDMARD, Conventional synthetic disease-modifying antirheumatic drug; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire Disability Index; IQR, Interquartile range; RF, Rheumatoid factor; SD, Standard deviation. bOf the patients who took the biologic in combination with a csDMARD, methotrexate was the comedication in 75.0% of patients in the abatacept group, in 91.4% in the rituximab group and in 86.0% in the TNFi group.